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Association of Parkinson Disease with Structural
and Regulatory Variants in the HLA Region
William T. Wissemann,1 Erin M. Hill-Burns,1 Cyrus P. Zabetian,2 Stewart A. Factor,3
Nikolaos Patsopoulos,4,5,6 Bryan Hoglund,7 Cherie Holcomb,7 Ryan J. Donahue,1 Glenys Thomson,8
Henry Erlich,7,9 and Haydeh Payami1,10,*
Historically, association of disease with the major histocompatibility complex (HLA) genes has been tested with HLA alleles that encode
antigen-binding affinity. The association with Parkinson disease (PD), however, was discovered with noncoding SNPs in a genome-wide
association study (GWAS). We show here that several HLA-region SNPs that have since been associated with PD form two blocks tagged
by rs3129882 (p¼ 93 1011) and by rs9268515 and/or rs2395163 (p¼ 33 1011). We investigated whether these SNP-associations were
driven by HLA-alleles at adjacent loci. We imputed class I and class II HLA-alleles for 2000 PD cases and 1986 controls from the
NeuroGenetics Research Consortium GWAS and sequenced a subset of 194 cases and 204 controls. We were therefore able to assess
accuracy of two imputation algorithms against next-generation-sequencing while taking advantage of the larger imputed data sets
for disease study. Additionally, we imputed HLA alleles for 843 cases and 856 controls from another GWAS for replication. PD risk
was positively associated with the B*07:02_C*07:02_DRB5*01_DRB1*15:01_DQA1*01:02_DQB1*06:02 haplotype and negatively
associated with the C*03:04, DRB1*04:04 and DQA1*03:01 alleles. The risk haplotype and DQA1*03:01 lost significance when con-
ditioned on the SNPs, but C*03:04 (OR¼ 0.72, p¼ 83 106) andDRB1*04:04 (OR¼ 0.65, p¼ 43 105) remained significant. Similarly,
rs3129882 and the closely linked rs9268515 and rs2395163 remained significant irrespective of HLA alleles. rs3129882 and rs2395163
are expression quantitative trait loci (eQTLs) forHLA-DR andHLA-DQ (93 105R PeQTLR 23 10
79), suggesting thatHLA gene expres-
sion might influence PD. Our data suggest that PD is associated with both structural and regulatory elements in HLA. Furthermore, our
study demonstrates that noncoding SNPs in the HLA region can be associated with disease irrespective of HLA alleles, and that observed
associations with HLA alleles can sometimes be secondary to a noncoding variant.HLA is one of the most complex regions in the human
genome because it has a high density of closely linked
genes, extreme polymorphism, and complicated patterns
of linkage disequilibrium (LD) (Figure 1). HLA class I and
class II genes encode molecules that bind antigens and
present them to T cell receptors, a function that is critical
for adaptive immune responses. HLA is associated with
numerous autoimmune, infectious, malignant, and neuro-
logic disorders. These associations have been established
with the classical HLA alleles, i.e., those that encode
structural variations that affect antigen-binding affinity.
However, the association of HLA with Parkinson’s disease
(PD [MIM 168600]) was discovered with noncoding
SNPs in a genome-wide association study (GWAS).1 Sub-
sequently, several other GWASs and SNP-based studies
confirmed the association of PD with HLA and identified
additional HLA-region SNPs that strongly associate with
risk of PD.2–6 The original PD-associated SNP,1 rs3129882,
is in intron 1 of HLA-DRA (MIM 142860). The other PD-
associated SNPs are also noncoding and map intergenicaly
near HLA-DRA, HLA-DRB1 (MIM 142857), and HLA-DRB5
(MIM 604776) (Figure 1). It is possible that these SNPs1Division of Genetics, Wadsworth Center, New York State Department of Health
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classical HLA polymorphisms is quite plausible for PD
because of the evidence for neuroinflammation in PD
pathogenesis.7 However, the few studies that have been
attempted with HLA alleles have had small sample sizes
and have produced discordant results.5,8 It is therefore
unknown whether the SNPs that have been associated
with PD tag specific HLA alleles, tag other genes, or repre-
sent regulatory elements (eQTLs).
Our aim was to determine whether PD is associated with
HLA alleles and whether the associations with SNPs were
driven by those HLA alleles. To that end, we used two
GWAS data sets: NGRC,1 which was the original GWAS
that uncovered the association of PD with HLA (2,000
PD cases and 1,986 controls), and PROGENI-GenePD9
(843 cases and 856 controls) for replication (NGRC and
PROGENI-GenePD data are available on dbGaP [search
terms CIDR and parkinson for the latter]; see Web
Resources). Both data sets were composed of unrelated
cases and controls of European descent and have been
described in detail elsewhere.1,9 In both data sets, neuro-
logists diagnosed PD by using standard research criteria10, Albany, NY 12208, USA; 2Veterans Affairs Puget Sound Health Care System
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Figure 1. HLA and PD-Associated
Variants
(A) Map of HLA class I and class II genes.
(B) PD-associated SNPs from our studies
and the literature.
(C) Linkage disequilibrium, measured by
correlation coefficient (r2 values shown in
boxes), among five PD-associated SNPs
and 12 PD-associatedHLA alleles identified
in the present study. rs41269955 is the
proxy used for rs75855844 in NGRC.and found the disease to be of late onset (average onset age
was 585 11 years in NGRC, 625 11 years in the replica-
tion data set), representing common idiopathic disease.
Both data sets are on the dbGaP website and have
undergone careful quality control, including in-depth
investigation of population structure.1,9 A concern that
the association of HLA with PD was driven by the associa-
tion of HLA with principal components was ruled out.1
The study was approved by the institutional review boards
of the participating institutions, and proper informed
consent was obtained.
Our first task was to generate the classical HLA alleles in
the NGRC and replication data sets. Next-generation
sequencing (NGS)11 is the gold standard but is prohibi-
tively costly for large-scale studies. We therefore used
imputation for the entire cohorts and sequenced class II
exons for 194 cases and 204 controls from NGRC. We
were therefore able to assess the accuracy of imputation
against NGS while taking advantage of the larger imputed
data sets for disease studies. Two algorithms have recently
been developed for imputing HLA alleles from SNP data:
SNP2HLA12 and HLA*IMP.13 Because there has not yet
been a head-to-head comparison of the performance of
the two methods, we applied both methods to the same
GWAS data set (NGRC). Both algorithms use extended
HLA-region SNP data fromGWAS to impute theHLA alleles
at 4-digit resolution for class I (A [MIM 142800], B [MIM
142830], and C [MIM 142840]) and class II (DRB1, DQA1
[MIM 146880], DQB1 [MIM 604305], and DPB1 [MIM
142858]) loci. DRB3 (MIM 612735), DRB4, and DRB5,
which are present on a subset of chromosomes, wereThe American Journal of Human Genimputed with HLA*IMP and at 2
digits. The effective N of imputed
data was 2,000 cases and 1,986 con-
trols for NGRC and 843 cases and
856 controls for the replication data
set. For NGS, we used DNA from
whole blood and sequenced exon 2
of class II loci DRB1, DRB3, DRB4,
DRB5, DQA1, and DPB1 and exons 2
and 3 of DQB1 alleles by using an
amplicon-sequencing strategy with
‘‘fusion’’ primers on the Roche 454
GS FLX instrument with Conexio
Genomics software as described else-where.11 Calls were made at 4-digit resolution or higher.
For nine individuals, NGS and imputation were highly
discordant, suggesting sample mix-up in plating. After
removal of these individuals, the effective N for NGS was
194 cases and 204 controls.
We assessed the accuracy of imputation for class II genes
by comparing data generated by each imputation algo-
rithm to data generated by NGS. For each individual, the
best-guess imputed alleles were compared to NGS-called
alleles and designated asmatches ormismatches. The accu-
racy of imputation was measured by sensitivity (SS: proba-
bility of calling an allele as being present correctly) and
specificity (SP: probability of calling an allele as being
absent correctly). Table S1 (in the Supplemental Data avail-
able with this article online) shows sensitivity and
specificity of SNP2HLA and HLA*IMP, side-by-side, as
compared to NGS. We found accuracy of imputation to
be generally high, in line with the values reported by the
authors of the algorithms.12,13 DQA1, DQB1, and DPB1
imputed better than DRB1, as was also the case in the orig-
inal papers.12,13 Both algorithms had trouble calling some
alleles (e.g., DRB1*01:03) or distinguishing certain DRB1
variants (e.g., DRB1*14 and *08 alleles) that might have
been generated by gene conversion. For some alleles (e.g.,
DPB1*10:01 or DRB1*14:01), one algorithm did well while
the other did poorly. We did not sequence class I genes
because we had no reason to suspect an association with
class I genes; however, because we did find an association
with an HLA-C allele, we should note that the original
imputation papers have reported >97% accuracy for
imputed HLA-C.12,13 We used the imputed data for diseaseetics 93, 984–993, November 7, 2013 985
Table 1. Association of PD with HLA Alleles
HLA Alleles
Allele Frequency in NGRC NGRC Replication Meta-Analysis
PD Control OR p OR p OR p
B*07:02 0.15 0.13 1.20 8 3 103 1.31 0.01 1.23 3 3 104
B*40:01 0.05 0.06 0.79 0.02 0.71 0.03 0.76 2 3 103
C*03:04 0.07 0.09 0.76 2 3 103 0.63 6 3 104 0.72 8 3 106
C*07:02 0.16 0.14 1.22 3 3 103 1.25 0.03 1.23 2 3 104
DRB1*04:04 0.03 0.05 0.64 5 3 104 0.67 0.03 0.65 4 3 105
DRB1*15:01 0.16 0.13 1.26 9 3 104 1.26 0.02 1.26 6 3 105
DRB4*01 0.26 0.29 0.85 3 3 103 0.80 4 3 103 0.83 4 3 105
DRB5*01 0.16 0.14 1.25 8 3 104 1.25 0.03 1.25 5 3 105
DQA1*01:02 0.22 0.20 1.15 0.02 1.22 0.02 1.17 1 3 103
DQA1*03:01 0.15 0.19 0.77 1 3 104 0.76 3 3 103 0.77 1 3 106
DQB1*03:02 0.09 0.11 0.75 3 3 104 0.73 7 3 103 0.74 7 3 106
DQB1*06:02 0.16 0.13 1.26 7 3 104 1.27 0.02 1.26 4 3 105
Class I and class II HLA alleles with frequencyR 0.01 were tested in NGRC. Fourteen alleles with p< 0.05 for association with PD were tested for replication. Twelve
that replicated are shown. Tests were conducted under the additive model and adjusted for principal components 1 and 2. p values (including those for the
replication data set) are two sided and uncorrected for multiple testing. The Bonferroni-corrected threshold for 14 tests is p ¼ 3 3 103.study because of the larger sample size with the caveat that
some alleles did not impute well and will require addi-
tional scrutiny. We show later that for the present study
imputed data were quite reliable.
Next, we tested association of the HLA alleles with PD
risk in NGRC. In the original GWAS that revealed the asso-
ciation of HLA with PD, the association was strong in
nonfamilial (simplex) PD and absent in familial PD.1
Therefore, for association testing, we excluded 435 cases
who reported a positive family history. We analyzed the
imputed genotypes for 1,565 simplex PD cases and 1,986
controls, once by using the imputed dosage probabilities
generated by SNP2HLA and again by using best-guess calls
from HLA*IMP. We excluded alleles with frequency <1%.
We used logistic regression in the R software to calculate
odds ratios (ORs), standard errors (SEs), and p values. All
tests were adjusted for two principal components (PC1
and PC2).1 Additional covariates (e.g., the presence or
absence of certain HLA alleles, haplotypes, or SNP geno-
types) were added for conditional analyses. p values are
reported for two-sided tests, without multiple-testing
correction. To be sure we did not miss any HLA variant
that might explain the SNP associations, we set the signif-
icance threshold low, at uncorrected p< 0.05, to minimize
false negatives. Alleles with p < 0.05 for association with
PD in NGRC were carried to replication. Analyses in repli-
cation were similar except that significance was set at a
Bonferroni-corrected p ¼ 3 3 103 (for 14 alleles carried
to replication). Replication testing was also adjusted for
PC1 and PC2 (and repeated with PC1 and PC4 as covariates
because PC4 was nominally significant; results were
unchanged). Lastly, we combined NGRC and replication
in a Meta-analysis conducted in the PLINK software.14986 The American Journal of Human Genetics 93, 984–993, NovembIn NGRC, 14 HLA alleles gave p < 0.05 for association
with PD. The same 14 alleles were identified whether we
used the data generated by SNP2HLA or that generated by
HLA*IMP. From here on, unless noted, we used the
HLA*IMP data. Of the 14 alleles with p < 0.05 in NGRC,
12 replicated in the seconddata set (Table 1); these included
two alleles each atC, B,DRB1,DQA1, andDQB1 loci, as well
asDRB4*01 andDRB5*01. Six of the alleles were associated
with increased risk and sixwith reduced risk of PD. Todeter-
mine whether the alleles were in LD, we constructed the
HLA haplotypes by using the method implemented in the
BEAGLE software for inferring haplotypes for unrelated
individuals15 and calculated r2 and D0, either by using
Haploview v. 4.2,16 or by hand. The six ‘‘risk’’ alleles were
in high LD, forming a common haplotype: B*07:02_
C*07:02_DRB5*01_DRB1*15:01_DQA1*01:02_DQB1*06:02
(Table S2, ORNGRC ¼ 1.29, pNGRC ¼ 3 3 103; ORreplication ¼
1.38, and preplication ¼ 0.02; ORmeta ¼ 1.32 and pmeta ¼ 2 3
104). The six ‘‘protective’’ alleles also formed a haplo-
type, B*40:01_C*03:04_DRB4*01_DRB1*04:04_DQA1*03:
01_DQB1*03:02 (Table S2, ORNGRC ¼ 0.60, pNGRC ¼ 0.02;
ORreplication ¼ 0.52, and preplication ¼ 0.06; ORmeta ¼ 0.58
and pmeta ¼ 3 3 103). However, the six protective alleles
were not in high LD (Figure 1). In conditional analysis,
where each allele was tested for association with PD while
adjustment was made for the other five alleles, three
seemingly independent association signals were detected
with C*03:04, DRB1*04:04 and DQA1*03:01 (Table S3). To
summarize thus far, we have identified and replicated four
associations between PD and classical HLA variants: a risk
haplotype, a protective class I allele, and two protective class
II alleles. (We will show that two of these classical associa-
tions are driven by SNPs.)er 7, 2013
Table 2. Association of PD with SNPs in the HLA Region
Previously Published PD-Associated SNPs
Allele Freqeuncy
in NGRC
Present Study
SNP
(Reference) BP Location Gene
Original Report NGRC Replication Meta-analysis
OR p PD Control OR p OR p OR p
rs31298821 32,409,530 intron 1 DRA 1.31 3 3 108 0.47 0.40 original report 1.21 5 3 103 1.30 9 3 1011
rs92685153 32,379,295 intergenic BTNL2-DRA 0.80 4 3 104 0.15 0.20 original report 0.75 5 3 103 0.75 8 3 108
rs758558442 32,480,227 intergenic DRA-DRB5 0.70 1 3 108 0.16 0.20 0.80 4 3 104 0.82 0.02 0.78 8 3 109
rs6608955 32,577,380 intergenic DRB1-DQA1 0.86 1 3 103 0.18 0.21 0.83 2 3 103 0.81 0.02 0.80 8 3 107
rs23951634 32,387,809 intergenic BTNL2-DRA 0.81 3 3 1011 0.19 0.23 0.77 2 3 105 0.78 3 3 103 0.81 3 3 1011
rs42481666 32,366,421 intergenic BTNL2-DRA 1.32 4 3 105 0.16 0.17 0.98 0.72 0.94 0.50 1.08 0.07
The HLA-region SNPs that have been previously reported as being associated with PD are shown with the originally reported findings and the results in the two
data sets used here. Tests were conducted under the additive model and adjusted for principal components 1 and 2. rs75855844 (chr6:32,588,205) could not be
generated. Two different SNPs were used as proxies in NGRC and replication data sets. rs2395163 was from a published meta-analysis that included NGRC and
replication data sets. The meta-analysis result shown here is that of the original report.The following SNPs in theHLA regionhave been reported
as being associated with the risk of PD: rs3129882,1
rs75855844,2 rs9268515,3 rs2395163,4 rs660895,5 and
rs42481666 (Table 2). rs3129882, rs660895, rs2395163,
and rs4248166 were genotyped on the GWAS arrays both
for NGRC and the replication data set. rs9268515 was also
genotyped in NGRC, and we imputed it into the
replication data set (info_score ¼ 0.96) by using the
IMPUTE2.2.2 software17 and the 1000 Genomes phase I in-
tegrated variant set (release v3, April 2012) as the reference
panel. We were unable to generate rs75855844 genotypes
(this SNP was not on the GWAS arrays or in 1000 Genomes
phase I, and it was removed from ImmunoChip calls by
technical filtering); we therefore used the best imputed
proxies, rs41269955 (info_score ¼ 0.99) in NGRC and
rs77539933 (info_score ¼ 0.86) in the replication data set
(r2 ¼ 1 with each other, r2 ¼ 0.75 with rs75855844 in
1000 Genomes Pilot 1). rs4248166 was not associated
with PD in NGRC or in the replication data set, and thus
we did not pursue it further. The LD structure constructed
in the NGRC data for the five PD-associated SNPs (Figure 1)
suggests that rs3129882 is not strongly correlated with the
other four SNPs (0.06 % r2 % 0.16). Whereas rs9268515,
rs41269955, and rs77539933 (the latter two of which
were used as proxies for rs75855844), rs660895, and
rs2395163 are in moderate LD with each other (0.52 %
r2 % 0.77) and therefore might be tagging the same PD-
associated factor. In fact, adjusting for either rs9268515
or rs2395163 abolished the association signals for
rs41269955, rs77539933, and rs660895 (Table S4). Thus,
the PD-associated SNPs in HLA might represent two
disease-associated elements, which in our study are best
tagged by rs3129882 and by rs9268515 and/or rs2395163.
To test the hypothesis that SNP associations are driven
by HLA alleles, we performed conditional and stratified
analysis and expected the association signal for the SNPs
to be lost when conditioned on the HLA variants. To the
contrary, the association of rs3129882 with PD and thatThe Americanof tightly linked rs9268515 and rs2395163, remained sig-
nificant irrespective of the HLA variants (Table 3 and Table
S5). When adjusted for HLA, significance dropped slightly,
possibly as a result of a loss of power after adjustment and
low levels of LD. For example, rs3129882 dropped from
having p ¼ 9 3 1011 to pconditioned % 2 3 109 when
adjustment was made for DRB1*04:04 or C*03:04 and to
pconditioned ¼ 3 3 108 when conditioned on the ‘‘risk’’
haplotype. Similarly, rs2395163 dropped from having
p ¼ 2 3 107 to pconditioned ¼ 3 3 106 when adjustment
was made for the ‘‘risk’’ haplotype and to pconditioned %
5 3 105 when adjustment was made for DRB1*04:04 or
C*03:04. Stratified analysis demonstrated a significant
association of SNPs with PD even in the absence of the
associated haplotypes (Table S6). These results indicate
that SNP associations were not driven by HLA alleles.
In reciprocal experiments, i.e., testing association ofHLA
with PD conditioned on SNPs (Table 4 and Table S7), the
signal for the ‘‘risk’’ haplotype B*07:02_C*07:02_DRB5*
01_DRB1*15:01_DQA1*01:02_DQB1*06:02 was lost to
rs3129882 (ORconditioned ¼ 1.13, pconditioned ¼ 0.1). We
did not find evidence of association for this haplotype in
stratified analysis either (Table S6). Because of strong LD
(D0 ¼ 0.83–1.0), the haplotype did not occur in the absence
of the rs3129882_G risk allele, and it was not associated
with PD in rs3129882_GA or rs3129882_GG individuals.
LD with rs3129882 was responsible for the association of
this haplotype with PD.
As for the ‘‘protective’’ HLA alleles, adjusting for
rs2395163 or rs9268515 abolished the DQA1*03:01 signal
(p ¼ 1 3 106 to pconditioned ¼ 0.2–0.3). However,
DRB1*04:04 and C*03:04 retained their effect sizes and sig-
nificance after being adjusted for every SNP (Table 4).
C*03:04 was reduced from OR ¼ 0.72, p ¼ 8 3 106 to
0.75 % ORconditioned % 0.80, 1 3 10
4 % pconditioned %
4 3 103. Similarly, DRB1*04:04 went from OR ¼ 0.65,
p ¼ 4 3 105 to 0.71 % ORconditioned % 0.75, 1 3 103 %
pconditioned % 0.01. These results are not likely to beJournal of Human Genetics 93, 984–993, November 7, 2013 987
Table 3. Association of SNPs with PD after Conditioning on HLA Alleles
NGRC Replication Meta-analysis
rs3129882 rs9268515 rs2395163 rs3129882 rs9268515 rs2395163 rs3129882 rs9268515 rs2395163
OR p OR p OR p OR p OR p OR p OR p OR p OR p
Not conditioned 1.35 1 3 109 0.74 5 3 106 0.77 2 3 105 1.20 0.01 0.75 5 3 103 0.78 3 3 103 1.30 9 3 1011 0.75 8 3 108 0.77 2 3 107
SNP Association with PD after Conditioning on HLA Alleles
B*07:02 1.33 2 3 108 0.75 1 3 105 0.78 5 3 105 1.16 0.04 0.77 8 3 103 0.79 6 3 103 1.27 6 3 109 0.76 3 3 107 0.78 9 3 107
C*03:04 1.33 6 3 109 0.76 5 3 105 0.79 1 3 104 1.17 0.02 0.80 0.03 0.81 0.01 1.28 1 3 109 0.78 5 3 106 0.80 5 3 106
C*07:02 1.32 3 3 108 0.75 2 3 105 0.78 6 3 105 1.17 0.03 0.76 7 3 103 0.79 5 3 103 1.27 7 3 109 0.76 4 3 107 0.78 1 3 106
DRB1*04:04 1.32 1 3 108 0.78 4 3 104 0.81 1 3 103 1.18 0.02 0.81 0.05 0.81 0.02 1.27 2 3 109 0.79 6 3 105 0.81 5 3 105
DRB1*15:01 1.33 2 3 107 0.77 8 3 105 0.80 3 3 104 1.15 0.08 0.78 0.01 0.80 0.01 1.27 2 3 107 0.77 3 3 106 0.80 8 3 106
DRB5*01 1.33 3 3 107 0.77 9 3 105 0.80 3 3 104 1.15 0.08 0.78 0.01 0.80 0.01 1.27 2 3 107 0.77 3 3 106 0.80 8 3 106
DQA1*01:02 1.35 1 3 108 0.76 4 3 105 0.78 1 3 104 1.15 0.06 0.78 0.01 0.80 0.01 1.28 1 3 108 0.76 2 3 106 0.79 5 3 106
DQA1*03:01 1.30 3 3 107 0.78 0.02 0.82 0.04 1.13 0.09 0.85 0.3 0.88 0.3 1.24 2 3 107 0.80 0.01 0.84 0.03
DQB1*06:02 1.33 3 3 107 0.77 8 3 105 0.80 3 3 104 1.15 0.08 0.78 0.01 0.80 0.01 1.26 2 3 107 0.77 3 3 106 0.80 8 3 106
SNP Association with PD after Conditioning on Haplotypes
B*07:02_C*07:02 1.33 2 3 108 0.75 1 3 105 0.78 5 3 105 1.16 0.03 0.77 8 3 103 0.79 6 3 103 1.27 6 3 109 0.76 3 3 107 0.78 9 3 107
DRB5*01_DRB1*15:01_DQA1*01:02_DQB1*
06:02
1.33 3 3 107 0.77 8 3 105 0.80 3 3 104 1.15 0.08 0.78 0.01 0.80 0.01 1.27 2 3 107 0.77 3 3 106 0.80 8 3 106
B*07:02_C*07:02_DRB5*01_DRB1*
15:01_DQA1*01:02_DQB1*06:02
1.33 5 3 108 0.76 4 3 105 0.79 1 3 104 1.15 0.06 0.77 9 3 103 0.79 7 3 103 1.27 3 3 108 0.76 1 3 106 0.79 3 3 106
This table displays the PD-associated SNPs that remained significant after being conditioned on other SNPs (Table S4); similarly, it includes only the PD-associated HLA-alleles that remained significant after being conditioned
on other HLA-alleles (Table S3). For a comprehensive analysis with all PD-associated SNPs and all HLA-alleles see Table S5. P values are two sided for all analyses (including replication) and not corrected for multiple testing.
Tests were adjusted for principal components 1 and 2.
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Table 4. Association of HLA Alleles with PD after Conditioning on SNPs
NGRC Replication Meta-analysis
Not
conditioned rs3129882 rs9268515 rs2395163
Not
conditioned rs3129882 rs9268515 rs2395163
Not
conditioned rs3129882 rs9268515 rs2395163
OR p OR P OR p OR p OR p OR p OR p OR p OR p OR p OR p OR p
Association of HLA Alleles with PD after Conditioning on SNPs
B*07:02 1.20 8 3 103 1.09 0.2 1.18 0.02 1.17 0.03 1.31 0.01 1.25 0.04 1.33 9 3
103
1.29 0.02 1.23 3 3 104 1.13 0.04 1.22 8 3 104 1.20 1 3 103
C*03:04 0.76 2 3 103 0.81 0.02 0.81 0.02 0.80 0.02 0.63 6 3
104
0.65 2 3
103
0.67 4 3
103
0.66 2 3
103
0.72 8 3 106 0.75 2 3
104
0.77 5 3 104 0.76 3 3 104
C*07:02 1.22 3 3 103 1.11 0.1 1.20 7 3
103
1.19 0.01 1.25 0.03 1.19 0.1 1.27 0.02 1.23 0.05 1.23 2 3 104 1.13 0.03 1.22 5 3 104 1.20 1 3 103
DRB1*04:04 0.64 5 3 104 0.71 8 3
103
0.75 0.03 0.75 0.03 0.67 0.03 0.70 0.05 0.70 0.09 0.77 0.2 0.65 4 3 105 0.71 1 3
103
0.73 7 3 103 0.75 0.01
DRB1*15:01 1.26 9 3 104 1.04 0.6 1.18 0.02 1.18 0.02 1.26 0.02 1.15 0.2 1.20 0.09 1.21 0.07 1.26 6 3 105 1.07 0.3 1.19 4 3 103 1.19 3 3 103
DRB5*01 1.25 8 3 104 1.04 0.6 1.18 0.02 1.18 0.02 1.25 0.03 1.13 0.3 1.18 0.1 1.19 0.08 1.25 5 3 105 1.07 0.3 1.18 4 3 103 1.18 3 3 103
DQA1*01:02 1.15 0.02 0.99 0.9 1.07 0.3 1.07 0.3 1.22 0.02 1.14 0.2 1.16 0.1 1.16 0.1 1.17 1 3 103 1.04 0.5 1.10 0.06 1.10 0.06
DQA1*03:01 0.77 1 3 104 0.87 0.04 0.94 0.5 0.92 0.5 0.76 3 3
103
0.80 0.02 0.85 0.3 0.85 0.3 0.77 1 3 106 0.84 3 3
103
0.91 0.3 0.90 0.2
DQB1*06:02 1.26 7 3 104 1.05 0.5 1.19 0.01 1.19 0.01 1.27 0.02 1.15 0.2 1.20 0.08 1.21 0.07 1.26 4 3 105 1.08 0.2 1.19 3 3 103 1.19 2 3 103
Haplotype Association with PD after Conditioning on SNPs
B*07:02_C*07:02 1.21 6 3 103 1.09 0.2 1.18 0.02 1.18 0.02 1.29 0.02 1.23 0.06 1.32 0.01 1.27 0.03 1.23 3 3 104 1.13 0.04 1.22 8 3 104 1.20 2 3 103
DRB5*01_DRB1*
15:01_DQA1*
01:02_DQB1*06:02
1.26 7 3 104 1.04 0.6 1.19 0.02 1.19 0.02 1.27 0.02 1.15 0.2 1.20 0.09 1.21 0.07 1.27 5 3 105 1.08 0.3 1.19 3 3 103 1.20 2 3 103
B*07:02_C*07:02_
DRB5*01_DRB1*
15:01_DQA1*01:02_
DQB1*06:02
1.29 3 3 103 1.08 0.4 1.22 0.03 1.22 0.03 1.38 0.02 1.26 0.1 1.34 0.04 1.33 0.04 1.32 2 3 104 1.13 0.1 1.25 3 3 103 1.25 3 3 103
This table displays the PD-associated SNPs that remained significant after being conditioned on other SNPs (Table S4); similarly, it includes only the PD-associated HLA alleles that remained significant after being conditioned
on other HLA alleles (Table S3). For a comprehensive analysis including all PD-associated SNPs and all HLA alleles, see Table S7. P values are two sided for all analyses (including those involving the replication data set) and are
not corrected for multiple testing. Tests were adjusted for principal components 1 and 2.
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Table 5. Step-wise Conditional Analysis of PD-Associated Variants
Allele
Round 1: Not
Conditioned
Round 2: Conditioned
on rs3129882
Round 3: Conditioned
on rs3129882 and C*03:04
Round 4: Conditioned on rs3129882,
C*03:04, and rs9268515
OR p OR p OR p OR p
rs3129882_G 1.30 9 3 1011 - - 1.28 1 3 1009 1.22 2 3 106
rs9268515_C 0.75 8 3 108 0.81 3 3 104 0.84 2 3 103 - -
rs2395163_C 0.77 2 3 107 0.86 5 3 103 0.88 0.02 1.00 0.97
DQA1*03:01 0.77 1 3 106 0.84 3 3 103 0.87 0.01 0.97 0.77
DQB1*03:02 0.74 7 3 106 0.82 3 3 103 0.86 0.03 0.92 0.33
C*03:04 0.72 8 3 106 0.75 2 3 104 - - 0.78 2 3 103
rs41269955/
rs77539933
0.81 2 3 105 0.88 0.02 0.90 0.05 0.97 0.67
DRB1*04:04 0.65 4 3 105 0.71 1 3 103 0.75 8 3 103 0.78 0.03
DQB1*06:02 1.26 4 3 105 1.08 0.24 1.07 0.26 1.06 0.37
DRB4*01 0.83 4 3 105 0.93 0.17 0.95 0.30 1.03 0.63
DRB5*01 1.25 5 3 105 1.07 0.30 1.06 0.35 1.05 0.49
DRB1*15:01 1.26 6 3 105 1.07 0.29 1.07 0.33 1.05 0.46
rs660895_G 0.82 9 3 105 0.88 0.02 0.91 0.07 1.02 0.74
C*07:02 1.23 2 3 104 1.13 0.03 1.11 0.08 1.13 0.04
B*07:02 1.23 3 3 104 1.13 0.04 1.11 0.08 1.12 0.05
DQA1*01:02 1.17 1 3 103 1.04 0.49 1.06 0.30 1.03 0.59
B*40:01 0.76 2 3 103 0.79 9 3 103 1.12 0.46 1.09 0.58
Five SNPs and 12 HLA variants that were individually associated with PD were included in the analysis (round 1). The marker with the strongest effect (in this case,
lowest p value, rs3129882) was selected as a covariate for successive analyses, and association tests were repeated (round 2) with conditioning on rs3129882. The
strongest effect in round 2 was associated with C*03:04. Round 3 tested remaining markers conditioned on rs3129882 and C*03:04. Round 4, with rs3129882, C*
03:04, and rs9268515 in the model, identified DRB1*04:04. No marker survived being adjusted for rs3129882, C*03:04, rs9268515, and DRB1*04:04.artifacts of imputation inaccuracy. The accuracy of imputa-
tion for the C locus is reportedly > 97%.12,13 Whereas
sensitivity of imputed DRB1*04:04 was only ~90%, NGS,
free of imputation uncertainty, supported the associa-
tion of DRB1*04:04 with PD (OR ¼ 0.49, p ¼ 0.12,
power < 10%).
Step-wise conditional analysis18 sums up the findings
clearly (Table 5). We tested all 17 variants (12 HLA alleles
and 5 SNPs from Tables 1 and 2) that individually associ-
ated with PD and identified the associations in the order
of significance in successive rounds of conditional anal-
ysis. rs3129882 had the strongest effect and was followed
by C*03:04, rs9268515, and DRB1*04:04.
It is possible that the associated SNPs are tagging genes
that we did not test here. Exploring LD with our strongest
signal, rs3129882, we found no SNP that correlated with
r2 > 0.65. All SNPs with r2 > 0.2 mapped between 32.2
Mb and 32.7 Mb on chromosome 6; this region includes
class II genes and BTNL2 (MIM 606000) (Figure 1). The
BTNL2 SNP with strongest association with PD (OR ¼
1.31, p ¼ 2 3 107) lost its signal (ORconditioned ¼ 1.05,
pconditioned ¼ 0.53) when conditioned on rs3129882. These
data are not best suited to address the question of whether
any of these SNPs are tagging genes not tested here; failing990 The American Journal of Human Genetics 93, 984–993, Novembto find evidence for another gene does not negate the
possibility that one is present.
Regulation of gene expression is an alternative explana-
tion for association of disease with HLA.19–21 Interestingly,
SNPs that have emerged from GWAS are more likely to
be eQTLs than frequency-matched ‘‘control’’ SNPs.22
Increasing interest in eQTLs has led to the generation of
data sets where SNPs are tested for correlation with gene
expression genome-wide, and these data are now compiled
in publically available databases. We used three commonly
used online databases: Genevar, eQTL, and SCAN. Within
each database, we used published sources.We selected only
expression data sets that were generated on individuals of
European descent. We used data from immune-related
cells, including lymphoblastoid cell lines, T cells, and
monocytes, which might be better proxies for an HLA-
associated disease than skin or adipose. We specified each
of the five SNPs in turn and queried cis association with
expression of genes that lie within 1 Mb in each direction
of the SNP. We set the significance threshold at p % 1 3
104, which was corrected for multiple comparisons with
Bonferroni correction for five SNPs tested with 130 genes,
the average number for a 2 Mb region of HLA (UCSC
Genome Browser) if we assume that every gene was probeder 7, 2013
Table 6. eQTL Data: Association of PD-Associated SNPs with Expression of Genes in the HLA Region
PD-SNP Gene Expression p Specificity Browser Original Data Source
rs3129882 DRA 1 3 105, 7 3 104 unique Genevar Nica, 201123
DRA 4 3 105 unique eQTL Montgomery, 201024
DRB5 9 3 105 unique eQTL Montgomery, 201024
DQB1 3 3 1014 unique SCAN Gamazon, 201025
DQA2 2 3 107 100% DQA2, 88% DQA1 eQTL Stranger, 200726
DRB5 9 3 109 100% DRB5, 92% DRB1, 88% DRB3 Genevar Stranger, 201229
DRB5 4 3 105, 9 3 105 100% DRB5, 92% DRB1, 88% DRB3 Genevar Dimas, 200930
DQB2 3 3 1014 unknown SCAN Gamazon, 201025
DRB1 3 3 1014 unknown SCAN Gamazon, 201025
DRB3,4,5 3 3 1014 unknown SCAN Gamazon, 201025
rs2395163 and/or
rs9268515a
DQA1 5 3 1014, 5 3 1013 unique Genevar Nica, 201123
DQA2 1 3 106 unique eQTL Montgomery, 201024
DRB1 5 3 1016 100% DRB1, 94% DRB4, 92% DRB5,
82% DRB3
eQTL Zeller, 201027
DQA1 2 3 1079 100% DQA1, 98% DQA2, 74% DOA eQTL Zeller, 201027
DQA1 6 3 106 100% DQA1, 94% DQA2 eQTL Veyrieras, 200828
DQA2 9 3 1015 100% DQA2, 88% DQA1 eQTL Stranger, 200726
DQB1 2 3 1030 100% DQB1, 86% DQB2, 74% DRB5 eQTL Zeller, 201027
DRB5 1 3 1014 100% DRB5, 92% DRB1, 88% DRB3 eQTL Zeller, 201027
DRB5 3 3 106 100% DRB5, 92% DRB1, 88% DRB3 Genevar Stranger, 201229
PD-associated SNPs in the HLA region form two blocks tagged by rs3129882 and by rs9268515 and/or rs2395163. The table shows the evidence, from three
publically available databases (browser), of association of rs3129882 and rs2395163 with the expression of genes within 1 Mb of the SNP. For additional
data, including evidence for association of rs660895 with HLA genes,23, 24, 26, 28, 29, 31 see Table S8. We used data that were collected from immune-related cells
of individuals of European origin. SNP-gene associations that passed Bonferroni-corrected significance are shown. Rows that have two p values denote indepen-
dent confirmation in co-twins or in two different tissues. We went back to the original data sources to determine the specificity of each probe to the identified gene
and its allelic variants (see Table S8 for details). Specificity denotes whether the probe hybridized with only one gene or with multiple genes. ‘‘Unique’’ denotes
when probe hybridized with only one gene with a 100% sequence match. Percentages denote the nucleotide match between the probe (usually 50 nucleotides)
and the targeted sequences. Except in one case, the probes were against a functionally nonpolymorphic gene (e.g., DRA) or the 30-UTR, and therefore allele spec-
ificity was not of relevance. In the one exception (see rs2395163, DQB1, Zeller, 201027) where the probe mapped to exon 4, it was a 100%match to all DQB1*02
alleles, 98% to DQB1*03, and DQB1*04 alleles, 82%–92% to DQB1*06 alleles, and 82%–88% to DQB1*05 alleles.
ars9268515 was not included in any of the eQTL databases, but rs2395163, which is in LD with rs9268515 (D’ ¼ 0.9, r2 ¼ 0.67), was in several databases.during expression analysis. As noted above, PD-associated
SNPs form two blocks, best tagged by 3129882 and by
rs9268515 and/or rs2395163. We found that rs3129882
is an eQTL for DRA (p ¼ 4 3 105; p ¼ 1 3 105),23,24
DRB (p ¼ 3 3 1014),25 DQA2 (p ¼ 2 3 107),26 and
DQB1 (p ¼ 3 3 1014).25 rs9268515 was not included in
any of the eQTL studies. rs2395163 (r2 ¼ 0.67, D0 ¼ 0.90
with rs9268515) was associated with expression of DQA1
(p ¼ 5 3 1014, p ¼ 5 3 1013, p ¼ 2 3 1079, p ¼ 6 3
106),23,27,28 DRB1 (p ¼ 5 3 1016),27 DQA2 (p ¼ 1 3
106, p ¼ 9 3 1015),24,26 and DQB1 (p ¼ 2 3 1030).27
rs660895, which is in the same LD block as rs9268515
and rs2395163 (r2 ¼ 0.55, D0 ¼ 0.77), was also associated
with expression levels of DQA1 (p ¼ 2 3 1017; p ¼ 1 3
1013; p ¼ 6 3 1011)23,28 and DQA2 (p ¼ 6 3 107; p ¼
1 3 1021)24,26 (Table 6 and Table S8). These findings
suggest that PD susceptibility might be influenced by
HLA expression levels, a viable hypothesis that should be
tested rigorously in the future.The AmericanHigh homology among HLA genes raises the concern
that probes might cross-react with more than one gene.
For experiments conducted withmicroarrays, we identified
the probes from the original experiment and assessed the
gene specificity of each probe by blasting it against the
NCBI whole-genome sequence and RNA reference
sequence, and we then assessed allele specificity of the
probe by using the IMGT/HLA Database. For the RNASeq
experiment, we confirmed that all multimapped reads
were filtered out (S. Montgomery, personal communica-
tion). Indeed, homology among DRB loci prevents assign-
ment of some eQTLs unambiguously; otherwise, there
were several probes that had perfect homology with one
gene and no cross-reactivity with any others (Table 6).
These unique specificities linked rs3129882 with the
expression of DRA and DQB1 and linked rs2395163/
rs9268515 with the expression of DQA1 and DQA2.
In summary,with the caveats thatHLA studies canbevery
complex and that the winner’s curse prevents conclusionsJournal of Human Genetics 93, 984–993, November 7, 2013 991
tobedrawnwith total confidence, our results suggest the ex-
istence of more than one HLA-region factor that affects PD
risk, represented by the predisposing effect of rs3129882
and the protective effects of C*03:04, DRB1*04:04, and
the closely linked SNPs rs9268515, rs2395163, and
rs660895. The PD-associated SNPs are most likely eQTLs.
Whether the protective factors that are represented by
C*03:04 andDRB1*04:04 are classical variants affecting an-
tigen binding affinity or regulatory elements affecting gene
expression levels is unknown. We have not excluded the
possibility that one or more of the SNPs tags another gene.
Wehave not demonstrated a direct cause-and-effect link be-
tweengene expression anddisease risk.However, the strong
association of SNPs with both PD risk and gene expression,
in the absence of evidence for involvement of classicalHLA
alleles, supports gene regulation as a viable mechanism for
association of HLA with PD. There is emerging evidence
for the importance ofHLA gene regulation in disease patho-
genesis,19–21 as exemplified by recent studies that have
shown that expression levels of HLA-C influence outcomes
of HIV infection.21 Our work demonstrates that noncoding
SNPs in HLA can be associated with disease irrespective of
classical HLA variants and that observed associations with
classicalHLAvariants can sometimes be secondary to anon-
coding variant. This realization is a sharp departure from
how studies of HLA-related diseases have been conducted
in the past, but it could be helpful for resolving the complex
roles that HLA genes play in disease pathogenesis.Supplemental Data
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